Literature DB >> 8514401

Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.

B J Young1, T R Kozel.   

Abstract

Incubation of encapsulated cells of Cryptococcus neoformans in normal human serum leads to activation of the alternative complement pathway and deposition of opsonic fragments of C3 into the capsule. We determined whether the variation in capsular structure that occurs among the four major cryptococcal serotypes was reflected in the kinetics for activation and binding of C3. We also examined the effects on activation kinetics of de-O-acetylation or periodate oxidation of the capsule. Binding kinetics were characterized in terms of the time required to deposit 5% of the maximal amount of C3 on the yeast (t5%), the first-order rate constant for amplification of C3 deposition (k'), and the maximum amount of C3 that could be deposited in the capsule (C3max). Our results showed that variations in the capsular structure that characterized each serotype had no significant influence on C3max but that the rate of C3 deposition depended significantly on the serotype. C3 accumulated at a higher rate on cells of serotypes A and D than on cells of serotypes B and C. There was a significant correlation between capsular volume and C3max, although the relationship was not linear. Periodate treatment of encapsulated cryptococci of all four serotypes led to decapsulation. Periodate-oxidized encapsulated cells displayed kinetics for activation and binding of C3 that were identical to kinetics observed with nonencapsulated cryptococci. Finally, de-O-acetylation led to a significant but relatively minor increase in C3max.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514401      PMCID: PMC280946          DOI: 10.1128/iai.61.7.2966-2972.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  On the structure of the capsular polysaccharide from Cryptococcus neoformans serotype C.

Authors:  A K Bhattacharjee; K J Kwon-Chung; C P Glaudemans
Journal:  Immunochemistry       Date:  1978-09

2.  Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; W H Welch
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

3.  Binding of cryptococcal polysaccharide to Cryptococcus neoformans.

Authors:  T R Kozel; C A Hermerath
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

4.  Structure determination of Cryptococcus neoformans serotype A-variant glucuronoxylomannan by 13C-n.m.r. spectroscopy.

Authors:  R Cherniak; R G Jones; E Reiss
Journal:  Carbohydr Res       Date:  1988-01-15       Impact factor: 2.104

5.  Species specificity of recognition by the alternative pathway of complement.

Authors:  R D Horstmann; M K Pangburn; H J Müller-Eberhard
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

6.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

7.  Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.

Authors:  R A Fromtling; H J Shadomy; E S Jacobson
Journal:  Mycopathologia       Date:  1982-07-23       Impact factor: 2.574

8.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

9.  Structural studies on the major, capsular polysaccharide from Cryptococcus bacillisporus serotype B.

Authors:  A K Bhattacharjee; K J Kwon-Chung; C P Glaudemans
Journal:  Carbohydr Res       Date:  1980-06       Impact factor: 2.104

10.  Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; J W Murphy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more
  36 in total

1.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

2.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

3.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

4.  Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells.

Authors:  T R Kozel; A Tabuni; B J Young; S M Levitz
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

5.  Reduced phagocytosis and killing of Cryptococcus neoformans biofilm-derived cells by J774.16 macrophages is associated with fungal capsular production and surface modification.

Authors:  Hiu Ham Lee; Jaclyn Del Pozzo; Sergio A Salamanca; Hazael Hernandez; Luis R Martinez
Journal:  Fungal Genet Biol       Date:  2019-07-26       Impact factor: 3.495

6.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

7.  Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells.

Authors:  S Schelenz; R Malhotra; R B Sim; U Holmskov; G J Bancroft
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America.

Authors:  Ashwin Dixit; Scott F Carroll; Salman T Qureshi
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.